N/A N=74 A Pychoeducational Intervention for Women With Diabetes
Depression · Anxiety · Anger
Primary: Center for Epidemiologic Studies Depression (CES-D) Score — 12.6; 21.5 units on a scale — p=.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=5 Data Acquisition Study for a Communication Device for Pediatric Patients With Cerebral Palsy
Cerebral Palsy
Primary: Speed of Communication — 8.13; 2.96 minutes
N/A N=12 Pharmacokinetics of Everolimus in Absorb BVS in Patients With Coronary Artery Lesions
Coronary Artery Disease · Coronary Artery Stenosis · Coronary Disease
Primary: Maximum Concentration (Cmax) — 2.397 nanograms per milliliter
Phase 2 N=105 Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z)
Pulmonary Tuberculosis
Primary: Early Bactericidal Activity (EBA) Measured as the Daily Rate of Change in log10 CFUs (Colony Forming Units) of M. Tuberculosis in Sputum on Solid Media (Days 0-14)…
Phase 3 N=587 Meta-Iodobenzylguanidine Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease
Heart Failure, Congestive
Primary: Relationship Between the Occurrence of Adverse Cardiac Event and 123I-mIBG Uptake on Planar Scintigraphy Categorized as High or Low Heart to Mediastinum (H/M) Ratio…
Phase 2 N=19 Double Blind Study to Evaluate the Efficacy of Collagenase Histolyticum in the Treatment of Lipoma
Lipoma
Primary: Percent Change From Baseline in Surface Area of the Lipoma at Six Months — -81.277; 2.053 percentage change from baseline — p=<0.0001
N/A N=327 Pilot Study Evaluating the Use of Simultaneous HBV, HCV, and HIV Rapid Tests
HIV · Hepatitis B · Hepatitis C
Primary: Accessibility of Testing Results — 0.642; 0.981 proportion of participants — p=<0.001
Phase 2 N=18 EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma
Leukemia-Lymphoma, Adult T-Cell
Primary: Tolerability of Treatment as Measured by Number of Participants With Grade 3 or Higher Adverse Events — 1; 1; 1; 2 participants
Phase 1 N=20 Bioavailability Food-Effect Study of an Oral Nitisinone Formulation to Treat Hereditary Tyrosinemia (HT-1)
Hereditary Tyrosinemia, Type I
Primary: Maximum Observed Plasma Concentration (Cmax) — 1168.23; 1054.32 ng/mL
Phase 3 N=526 Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
Arthritis, Rheumatoid
Primary: Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Week 24 — 74.6; 72.4 percentage of participants
Phase 1 N=60 Study of a Parenterally Administered H5N1 Influenza Vaccine in Healthy Adults
Influenza · Healthy
Primary: Solicted Adverse Events — 8; 12; 13; 14 participants
Phase 3 N=350 Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis
Psoriasis
Primary: Percent Improvement From Baseline in Psoriasis Area and Severity Index (PASI) at Week 16 — 80.91; 83.06 percent change
N/A N=1,000 Application of HBV Rapid Tests as a Tool for Wide-Use Screening
Hepatitis B · Liver Cirrhosis · Carcinoma, Hepatocellular
Primary: Percentage of Patients Appropriately Seeking Care — 5.7; 4.0 percentage of participants — p=0.5
Phase 3 N=403 A Study of Degarelix in Patients With Prostate Cancer
Prostate Cancer
Primary: Percentage of Patients With Serum PSA Levels ≤4.0 ng/mL — 100; 98.4 Percentage of patients
Phase 2 N=47 Study in Advanced Solid Tumors
Solid Tumor
Primary: Total Cisplatin Pharmacokinetics (PK): Area Under the Concentration (AUC) Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) — 324; 338 micrograms*hour/milliliters…